Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension
Status: Enrolling
Updated:  12/22/2015
Novartis Investigational
mi
from
Bryan, TX
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension
Status: Enrolling
Updated: 12/22/2015
Novartis Investigational
mi
from
Bryan, TX
Click here to add this to my saved trials
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension
Status: Enrolling
Updated:  12/22/2015
Novartis Investigative Site
mi
from
Houston, TX
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension
Status: Enrolling
Updated: 12/22/2015
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension
Status: Enrolling
Updated:  12/22/2015
Novartis Investigative Site
mi
from
Caba,
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension
Status: Enrolling
Updated: 12/22/2015
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
Epidemiology of Hypertensive Emergency
Correlates of Nonadherence to Hypertension Treatment in an Inner-City Minority Population
Status: Enrolling
Updated:  12/22/2015
Columbia University
mi
from
New York, NY
Epidemiology of Hypertensive Emergency
Correlates of Nonadherence to Hypertension Treatment in an Inner-City Minority Population
Status: Enrolling
Updated: 12/22/2015
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
A Randomized, Double-blind, Placebo Controlled, Parallel Study for the Assessment of Anti-hypertensive Effect and Safety of Marealis RPC (Refined Peptide Concentrate), in Healthy Subjects With Mild or Moderate Hypertension
Status: Enrolling
Updated:  12/23/2015
Biofortis
mi
from
Addison, IL
Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
A Randomized, Double-blind, Placebo Controlled, Parallel Study for the Assessment of Anti-hypertensive Effect and Safety of Marealis RPC (Refined Peptide Concentrate), in Healthy Subjects With Mild or Moderate Hypertension
Status: Enrolling
Updated: 12/23/2015
Biofortis
mi
from
Addison, IL
Click here to add this to my saved trials
Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
A Randomized, Double-blind, Placebo Controlled, Parallel Study for the Assessment of Anti-hypertensive Effect and Safety of Marealis RPC (Refined Peptide Concentrate), in Healthy Subjects With Mild or Moderate Hypertension
Status: Enrolling
Updated:  12/23/2015
Dr. William O'Mahony Medicine Professional Corporation
mi
from
Corunna,
Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
A Randomized, Double-blind, Placebo Controlled, Parallel Study for the Assessment of Anti-hypertensive Effect and Safety of Marealis RPC (Refined Peptide Concentrate), in Healthy Subjects With Mild or Moderate Hypertension
Status: Enrolling
Updated: 12/23/2015
Dr. William O'Mahony Medicine Professional Corporation
mi
from
Corunna,
Click here to add this to my saved trials
Necklace-Shaped Sensor for Non-Invasive Remote Monitoring of Vitals
Necklace-Shaped Sensor for Non-Invasive Monitoring of Fluids, Heart Rate, Heart Rate Variability, and Respiration Rate in Patients With a Pacemaker, Implanted Cardioverter-Defibrillator, or Ventricular Assist Device
Status: Enrolling
Updated:  12/28/2015
Imperial Cardiac Center
mi
from
Imperial, CA
Necklace-Shaped Sensor for Non-Invasive Remote Monitoring of Vitals
Necklace-Shaped Sensor for Non-Invasive Monitoring of Fluids, Heart Rate, Heart Rate Variability, and Respiration Rate in Patients With a Pacemaker, Implanted Cardioverter-Defibrillator, or Ventricular Assist Device
Status: Enrolling
Updated: 12/28/2015
Imperial Cardiac Center
mi
from
Imperial, CA
Click here to add this to my saved trials
Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/29/2015
LSUHSC Interim Louisiana Hospital
mi
from
New Orleans, LA
Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/29/2015
LSUHSC Interim Louisiana Hospital
mi
from
New Orleans, LA
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Tucson, AZ
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
La Jolla, CA
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Sacramento, CA
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Aurora, CO
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Weston, FL
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Weston, FL
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Chicago, IL
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Iowa City, IA
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Baltimore, MD
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Boston, MA
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Boston, MA
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Omaha, NE
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Newark, NJ
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
New York, NY
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Cleveland, OH
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Columbus, OH
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Fairfield, OH
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Fairfield, OH
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Providence, RI
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Dallas, TX
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
El Paso, TX
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
El Paso, TX
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
Clinical Research Facility
mi
from
Houston, TX
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated:  1/5/2016
mi
from
Graz,
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial
Status: Enrolling
Updated: 1/5/2016
mi
from
Graz,
Click here to add this to my saved trials
Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries
The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetics
Status: Enrolling
Updated:  1/8/2016
University of Chicago
mi
from
Chicago, IL
Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries
The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetics
Status: Enrolling
Updated: 1/8/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety Study of Nebivolol for COPD Patients
Nebivolol in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  1/11/2016
University of Chicago Medical Center
mi
from
Chicago, IL
Safety Study of Nebivolol for COPD Patients
Nebivolol in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 1/11/2016
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety of SonoVue on Pulmonary Hemodynamics
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Crossover, Safety Study of the Effect of Intravenous Bolus Injections of SonoVue on Pulmonary Hemodynamics in Subjects With and Without Pulmonary Hypertension
Status: Enrolling
Updated:  1/11/2016
Holy Name Medical Center
mi
from
Teaneck, NJ
Safety of SonoVue on Pulmonary Hemodynamics
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Crossover, Safety Study of the Effect of Intravenous Bolus Injections of SonoVue on Pulmonary Hemodynamics in Subjects With and Without Pulmonary Hypertension
Status: Enrolling
Updated: 1/11/2016
Holy Name Medical Center
mi
from
Teaneck, NJ
Click here to add this to my saved trials
Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Status: Enrolling
Updated:  1/11/2016
UT Southwestern Medical Center
mi
from
Dallas, TX
Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension
Status: Enrolling
Updated: 1/11/2016
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease
The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease
Status: Enrolling
Updated:  1/19/2016
New York Institute of Technology
mi
from
Old Westbury, NY
The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease
The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease
Status: Enrolling
Updated: 1/19/2016
New York Institute of Technology
mi
from
Old Westbury, NY
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
Cardiovascular Associates
mi
from
Birmingham, AL
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
Cardiovascular Associates
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
University of South Alabama
mi
from
Mobile, AL
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
University of South Alabama
mi
from
Mobile, AL
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
Arizona Pulmonary Specialists, Ltd.
mi
from
Phoenix, AZ
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
Arizona Pulmonary Specialists, Ltd.
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
Berkeley Cardiovascular Medical Group
mi
from
Berkeley, CA
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
Berkeley Cardiovascular Medical Group
mi
from
Berkeley, CA
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
Cedars Sinai Heart Institute
mi
from
Beverly Hills, CA
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
Cedars Sinai Heart Institute
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
University California San Francisco
mi
from
Fresno, CA
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
University California San Francisco
mi
from
Fresno, CA
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
University of Southern California
mi
from
Los Angeles, CA
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
West Los Angeles VA Healthcare Center
mi
from
Los Angeles, CA
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
West Los Angeles VA Healthcare Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
University of California, Davis Medical Center
mi
from
Sacramento, CA
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
Paloma Medical Group
mi
from
San Juan Capistrano, CA
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
Paloma Medical Group
mi
from
San Juan Capistrano, CA
Click here to add this to my saved trials
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated:  1/20/2016
Santa Barbara Cottage Hospital
mi
from
Santa Barbara, CA
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
Status: Enrolling
Updated: 1/20/2016
Santa Barbara Cottage Hospital
mi
from
Santa Barbara, CA
Click here to add this to my saved trials